"These findings are in line with those of the more than 800 patients I've treated personally to date, some of whom are up to seven years post-treatment," said Dr. Katz. "I am excited to see the body of long term data supporting the outcomes of CyberKnife prostate SBRT growing in support of this treatment's benefits for patients."During the press conference, Dr. Katz also spoke to the cost-benefits of CyberKnife SBRT, which he said "is less expensive than IMRT for a payer like Medicare, which can cost the government program upwards of $40,000 for a full round of treatments in some areas."
Presentations At Leading Radiation Oncology Meeting Highlight CyberKnife Prostate Outcomes From Patients At More Than 40 Centers
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.